Counterparty Risk in the Basel III Endgame: Capital, XVA and the New Pricing Discipline

Basel III finalisation is now substantially in force across major APAC markets, with SA‑CCR established as the framework for measuring derivatives exposures and determining capital requirements. For sell‑side institutions operating across jurisdictions, the operational reality of counterparty risk under the new capital rules is being tested at scale.

At the same time, rate volatility, widening credit dispersion and tighter funding conditions are intensifying balance‑sheet pressures. Elevated supervisory expectations around counterparty credit risk management have reinforced the need for stronger exposure monitoring, stress testing and governance. Counterparty risk is no longer a siloed control function — it is central to pricing discipline, capital efficiency and collateral strategy.
The question facing institutions is increasingly operational: how to manage credit exposure, capital charges, funding costs and collateral requirements within a single, coherent framework — and how to embed those dynamics into trade pricing and portfolio management without disrupting front‑office execution or risk oversight.

Regulation Asia invites senior APAC sell‑side practitioners to join Bloomberg’s risk specialists for a practitioner‑led discussion on how counterparty risk architecture is evolving in practice. The session will assess the real capital impact of SA‑CCR, the expanding role of XVA and collateral optimisation in pricing and balance‑sheet management, and the integration of risk, capital and trading analytics across jurisdictions — concluding with a forward‑looking assessment of supervisory priorities, capital efficiency pressures and the structural shifts institutions should prepare for over the next 12–18 months.